UK employers are facing mounting pressure to rethink their healthcare and benefits strategies as demand for weight-management drugs rises among employees, according to new research.
The Changing Face of Employee Health report by Howden Employee Benefits found that more than a quarter of UK workers have used medications such as Ozempic, and two in five believe their employer should cover access to these treatments through workplace healthcare plans. As a result, 44 per cent of employers said they are reviewing or redesigning their healthcare provision to respond to growing demand.
While the trend reflects increasing employee expectations, employers are confronting financial challenges. Nearly nine in ten businesses report being satisfied with the return on investment from their healthcare plans. Yet, for companies already covering weight-management drugs, half now see them as a rising cost concern. Around 50 per cent expect these expenses to climb further, and one in five businesses cited obesity-related conditions as the primary driver of increasing healthcare spending.
Only 5 per cent of employers anticipate costs will ease in the coming year, though many acknowledge that investing in preventive measures could reduce long-term health risks. Weight-related illnesses such as diabetes contribute to higher sickness absence and lost productivity, making controlled access to weight-management drugs an attractive option for some businesses. Currently, about 72 per cent of UK employers are investing in preventive health programs, the report noted.
Cheryl Brennan, managing director of Howden Employee Benefits, said the trend is forcing a rethink of plan design and budgeting. “The demand for these drugs is obvious, and employers simply can’t afford to ignore it. But the financial impact cannot be overlooked,” she said.
Brennan cautioned that weight-management medications are not a universal solution. “They need to sit within a broader, personalised health strategy with clear eligibility criteria. Employers will also have to justify why they cover these treatments ahead of others that remain excluded,” she added.
The report highlights the broader pressures facing workplace healthcare. With medical inflation projected at 7 per cent in 2026, and combined increases exceeding 10 per cent when general inflation is included, businesses must make difficult choices about which treatments to cover.
As employee expectations evolve, Howden’s research suggests workplace healthcare is entering a new phase. Companies will need to balance preventive strategies, personalised care, and financial trade-offs when shaping benefits in the coming years.
The study signals a shift in employer priorities, showing that weight-management drugs are no longer a niche concern but a defining issue for future healthcare provision in UK workplaces.
